Hot Investor Mandate 1: Pharmaceutical Business Arm of South Korean Conglomerate Seeking Early-Stage In-Licensing Opps in NASH and Immuno-oncology

4 Jan

A fully integrated pharmaceutical business that launched as a wholly-owned subsidiary of a large South Korea-based corporate is actively engaging in partnering with early-stage companies. The corporate is one of the largest conglomerates in South Korea, and a well-established leader in the food, feed, and biotech industry. Historically, the firm has had a successful track record of commercializing new drugs. The firm is actively seeking in-licensing and collaborative opportunities to add to their growing pipeline that covers areas of high, unmet medical need. The firm will seek opportunities globally.

The firm is currently seeking early-stage, in-licensing opportunities with strongest interest in antibodies and cell/gene therapies in nonalcoholic steatohepatitis (NASH) or immuno-oncology.

The firm is seeking to partner with early-stage companies developing novel therapeutics with management teams of strong scientific background and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: